What genetic variants are associated with Type 2 Diabetes?

Key pharmacogenomic variants: rs12255372 in TCF7L2, rs7903146 in TCF7L2. Genes involved: TCF7L2, KCNJ11, PPARG, SLC30A8.

How can PepFold help with Type 2 Diabetes research?

PepFold accepts the rsIDs associated with Type 2 Diabetes (rs12255372, rs7903146) and generates computational peptide candidates targeting the affected proteins. Each candidate comes with predicted 3D structures, 10-dimension scoring, and Fmoc-SPPS synthesis protocols.

Condition Database

Type 2 Diabetes

Prevalence: ~537 million adults worldwide (IDF 2021), ~10.5% of global adult population

A metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction. TCF7L2 variants are the strongest common genetic risk factors. GLP-1 receptor agonist peptides have revolutionized treatment.

Peptide Therapeutics

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) are blockbuster peptide therapeutics with >$30B annual sales. Dual and triple incretin agonists are expanding the class. This is the most commercially successful peptide therapeutic area.

Current Treatments

Semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro), liraglutide (Victoza), insulin analogs, metformin, SGLT2 inhibitors.

Key Genetic Variants

rs12255372~27% global allele frequency (T allele)

TCF7L2 — Intron 4 (G>T)

rs7903146~30% global (T allele)

TCF7L2 — Intron 3 (C>T)

Associated Genes

TCF7L2Transcription Factor 7-Like 2

Key transcription factor in the Wnt signaling pathway. Regulates incretin hormone expression (GLP-1, GIP) and pancreatic beta-cell proliferation and function.

KCNJ11Profile coming soon

PPARGProfile coming soon

SLC30A8Profile coming soon

Explore peptide candidates for Type 2 Diabetes

Submit rs12255372, rs7903146 to PepFold. Full report with 3D structures and synthesis protocols in under 2 minutes.

Try Analysis View Pricing